SEC Company Response from ProQR Therapeutics N.V. (PRQR) (CIK 0001612940) (PRQR) — Sep 16, 2014
ProQR Therapeutics N.V. (PRQR) (CIK 0001612940)
Date: Sept. 16, 2014 · CIK: 0001612940 · Accession: 0001193125-14-342300
AI Filing Summary & Sentiment
File numbers found in text: 333-198151
Letter
VIA EDGAR AND FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Attention: Jeffrey P. Riedler Re: ProQR Therapeutics B.V. Acceleration Request for Registration Statement on Form F-1 File No. 333-198151
Dear Mr. Reidler:
Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), ProQR Therapeutics B.V. (the “Company”) hereby requests that the effective date and time of the above-referenced registration statement (the “Registration Statement”) be accelerated to September 17, 2014, at 4:00 p.m., Eastern Time, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”). In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Danielle M. Lauzon at (617) 570-1955. We also respectfully request that a copy of the written order from the Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Danielle M. Lauzon, by facsimile to (617) 523-1231.
In connection with the foregoing, the Company hereby acknowledges the following:
•
should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement;
•
the action of the Commission or the staff of the Commission, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Under separate cover, Leerink Partners LLC and Deutsche Bank Securities Inc., as representatives of the underwriters, will send the Commission a letter joining in this request for acceleration of the effective date. The representatives will also provide you with information with respect to clearance from the Financial Industry Regulatory Authority prior to the effective date.
If you have any questions regarding this request, please contact Danielle M. Lauzon of Goodwin Procter LLP at (617) 570-1955.
Sincerely,
PROQR THERAPEUTICS B.V.
Show Raw Text
CORRESP 1 filename1.htm ACCELERATION REQUEST ProQR Therapeutics, B.V. Darwineg 24 2333 CR Leiden The Netherlands VIA EDGAR AND FEDERAL EXPRESS September 16, 2014 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549-4720 Attention: Jeffrey P. Riedler Re: ProQR Therapeutics B.V. Acceleration Request for Registration Statement on Form F-1 File No. 333-198151 Dear Mr. Reidler: Pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), ProQR Therapeutics B.V. (the “Company”) hereby requests that the effective date and time of the above-referenced registration statement (the “Registration Statement”) be accelerated to September 17, 2014, at 4:00 p.m., Eastern Time, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”). In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act. Once the Registration Statement is effective, please orally confirm the event with our counsel, Goodwin Procter LLP, by calling Danielle M. Lauzon at (617) 570-1955. We also respectfully request that a copy of the written order from the Commission verifying the effective time and date of the Registration Statement be sent to our counsel, Goodwin Procter LLP, Attention: Danielle M. Lauzon, by facsimile to (617) 523-1231. In connection with the foregoing, the Company hereby acknowledges the following: • should the Commission or the staff of the Commission, acting pursuant to delegated authority, declare the Registration Statement effective, it does not foreclose the Commission from taking any action with respect to the Registration Statement; • the action of the Commission or the staff of the Commission, acting pursuant to delegated authority, in declaring the Registration Statement effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the Registration Statement; and • the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Under separate cover, Leerink Partners LLC and Deutsche Bank Securities Inc., as representatives of the underwriters, will send the Commission a letter joining in this request for acceleration of the effective date. The representatives will also provide you with information with respect to clearance from the Financial Industry Regulatory Authority prior to the effective date. If you have any questions regarding this request, please contact Danielle M. Lauzon of Goodwin Procter LLP at (617) 570-1955. Sincerely, PROQR THERAPEUTICS B.V. /s/ Daniel de Boer Daniel de Boer Chief Executive Officer cc: André Verwei, ProQR Therapeutics B.V. René Beukema, ProQR Therapeutics B.V. Mitchell S. Bloom, Goodwin Procter LLP Danielle M. Lauzon, Goodwin Procter LLP Brian A. Johnson, Wilmer Cutler Pickering Hale and Dorr LLP Timothy J. Corbett, Wilmer Cutler Pickering Hale and Dorr LLP